Why do Waldenström’s and Myeloma Change from MGUS to Active Disease?

Earn CME for related activities: www.naccme.com/oln
For the past fifteen years, Lymphoma & Myeloma has been the premier forum on the latest advances in lymphoma, myeloma, and other plasma cell neoplasms. Over forty internationally recognized leaders in molecular biology, pathology, immunology, translational and clinical research have been involved to provide expertise and guidance on recent developments in the basic science, translational medicine and clinical trials.
This Congress features an interdisciplinary approach, special lectures, debates and interactive techniques to explore the controversial, the upcoming, and the exciting in myeloma, Waldenstrom’s macroglobulinemia, chronic lymphocytic leukemia, lymphoma and Hodgkin’s disease.
In this presentation, Dr. Irene M. Ghobrial discusses why Waldenstrom's and myeloma change from monoclonal gammopathy of undetermined significance (MGUS) to active disease.
© 2015 Imedex, LLC.

[@darcifletcher7297]

I wish you would slow down when you speak :(